Clinical Trial

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

Study acronym: MonumenTAL-6
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd).
Protocol Amendment History 1 change
minor Completion pushed: 2028-03-31 -> 2028-12-31 2026-06-04
Trial Details
NCT Number NCT06208150
Lead Sponsor Janssen Research & Development, LLC
Conditions Multiple Myeloma
Enrollment 795 participants
Start Date 2024-01-22
Primary Completion 2026-04-01 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-05